Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC. (PubMed, Target Oncol) - Oct 5, 2026 - "Three immunotherapy-based regimens are now approved for first-line treatment of advanced hepatocellular carcinoma: atezolizumab plus bevacizumab, durvalumab plus tremelimumab (STRIDE), and nivolumab plus ipilimumab. We further discuss why predictive biomarker development in advanced hepatocellular carcinoma has repeatedly failed to translate, including limited tissue availability, tumor and liver-disease heterogeneity, prognostic confounding, and reliance on single-treatment cohorts rather than treatment-by-biomarker interaction analyses. We propose that the most promising future selection tools will integrate tumor immune state with angiogenic, myeloid, and circulating molecular features and be prospectively tested across competing regimens and treatment sequences."
Biomarker • IO biomarker • Journal • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor
|
|
Alireza Tojjari; Anwaar Saeed
|